熱門資訊> 正文
Acrivon Therapeutics报告第四季度业绩
2025-03-28 17:20
- Acrivon Therapeutics press release (NASDAQ:ACRV): Q4 GAAP EPS of -$0.60.
- As of December 31, 2024, the company had cash, cash equivalents and investments of $184.6 million, which is expected to fund operating expenses and capital expenditure requirements into 2027.
More on Acrivon Therapeutics
- Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer
- Seeking Alpha’s Quant Rating on Acrivon Therapeutics
- Historical earnings data for Acrivon Therapeutics
- Financial information for Acrivon Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
